Healthcare · Pharmaceuticals & Biotechnology
The largest companies in the same industry by market cap. This company ranks #24 of 184. PE, ROE, 1Y return and scores come from the daily/weekly precomputed snapshot.
| Company | Market cap (₹ Cr) | PE (TTM) | ROE | 1Y return | Div. yield | Quality | Valuation | Momentum |
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | 427,010 | 143.5 | 13.7% | 7.6% | — | 72 | 8 | 30 |
| Divi's Laboratories Limited | 244,125 | 83.0 | 15.3% | 57.8% | 0.33% | 70 | 4 | 51 |
| Torrent Pharmaceuticals Limited | 161,506 | 77.7 | 12.2% | 35.3% | 0.80% | 56 | 0 | 31 |
| Zydus Lifesciences Limited | 113,616 | 32.6 | 17.3% | 14.5% | 0.09% | 74 | 24 | 84 |
| Cipla Limited | 107,888 | 35.1 | 11.2% | -11.7% | 0.97% | 73 | 29 | 62 |
| Laurus Labs Limited | 106,505 | 122.0 | 17.1% | 128.4% | — | 78 | 24 | 53 |
| Mankind Pharma Limited | 102,382 | 46.9 | 11.7% | 0.9% | — | 68 | 12 | 86 |
| Dr. Reddy's Laboratories Limited | 100,411 | 150.9 | 10.9% | -3.7% | — | 62 | 33 | 71 |
| Rubicon Research Limited (this stock) | 26,602 | 111.0 | — | — | 0.09% | 96 | 0 | 30 |
Current only. Market cap is the whole company's; sales/EBITDA are trailing-twelve-month standalone; debt and cash come from the latest filed standalone balance sheet (March 31, 2026). EBITDA = PBT + interest + depreciation.
| Period end | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) | Basic EPS |
|---|---|---|---|---|
| June 30, 2026 | 428 | 111 | 82 | ₹4.9900 |
| March 31, 2026 | 390 | 94 | 70 | ₹4.2500 |
| Dec. 31, 2025 | 302 | 50 | 37 | ₹2.2800 |
| Sept. 30, 2025 | 336 | 62 | 46 | ₹2.9700 |
| Indicator | Jun 26 | Mar 26 | Dec 25 | Sep 25 |
|---|---|---|---|---|
| Total income (before exceptional items) | 430 | 393 | 306 | 338 |
| Operating revenue | 428 | 390 | 302 | 336 |
| Other income | 2 | 4 | 4 | 2 |
| Operating expenses | 303 | 284 | 239 | 257 |
| Operating profit | 125 | 106 | 62 | 79 |
| Operating profit margin | 29.2% | 27.2% | 20.6% | 23.5% |
| Depreciation | 11 | 10 | 10 | 10 |
| Interest | 6 | 5 | 8 | 9 |
| Exceptional items, gain / (loss) | — | — | — | — |
| Profit before tax | 111 | 94 | 50 | 62 |
| Tax | 28 | 24 | 12 | 16 |
| Net profit | 82 | 70 | 37 | 46 |
| EPS | 4.99 | 4.25 | 2.28 | 2.97 |
| Net profit (TTM) | 235 | — | — | — |
| EPS (TTM) | 14.49 | — | — | — |
Total income excludes exceptional items, which are shown on their own row. Trendlyne and Screener fold exceptional items into revenue or other income, so their totals differ from this table by exactly that row.
| Year ended | Revenue (₹ Cr) | PBT (₹ Cr) | Net profit (₹ Cr) |
|---|---|---|---|
| March 31, 2026 | 1,306 | 253 | 188 |
| Indicator | CAGR 3Y | CAGR 5Y | Mar 26 |
|---|---|---|---|
| Total income (before exceptional items) | — | — | — |
| Operating revenue | — | — | 1,306 |
| Other income | — | — | — |
| Operating expenses | — | — | — |
| Operating profit | — | — | — |
| Operating profit margin | — | — | — |
| Depreciation | — | — | — |
| Interest | — | — | — |
| Exceptional items, gain / (loss) | — | — | — |
| Profit before tax | — | — | 253 |
| Tax | — | — | — |
| Net profit | — | — | 188 |
| EPS | — | — | — |
† Derived: the sum of that fiscal year's four quarterly filings (a real annual filing is used wherever one exists). Checked against filed annual figures, the sum lands within 0.5% for about 94% of company-years.
| Ratio | Mar 26 |
|---|---|
| Operating margin | — |
| EBIT margin | — |
| PBT margin | 19.4% |
| Net margin | 14.4% |
| Interest coverage | — |
| Dividend payout | — |
| Earnings retention | — |
| Current ratio | 3.10x |
| Quick ratio | 2.34x |
| Debt to equity | 0.19x |
| Return on equity | 13.9% |
| Return on assets | 9.5% |
| Return on capital employed | — |
| Asset turnover | 0.66x |
Margins and asset turnover use operating revenue (interest earned for banks, excluding other income), not total income. Liquidity, leverage and return ratios need a filed standalone balance sheet, which exists only for recent years; returns use year-end equity/assets. Dividend payout is shown only for companies with a dividend record. † = built from a summed fiscal year.
Data unavailable.
| Year ended | Operating (₹ Cr) | Investing (₹ Cr) | Financing (₹ Cr) | Capex (₹ Cr) | Free Cash Flow (₹ Cr) |
|---|---|---|---|---|---|
| March 31, 2026 | 39 | -272 | 297 | 195 | -156 |
| Year ended | Total Assets (₹ Cr) | Total Equity (₹ Cr) | Reserves (₹ Cr) | Borrowings, Current (₹ Cr) | Borrowings, Non-current (₹ Cr) | Current Assets (₹ Cr) | Current Liabilities (₹ Cr) | Cash & Equivalents (₹ Cr) | Net Block (₹ Cr) | Inventory (₹ Cr) |
|---|---|---|---|---|---|---|---|---|---|---|
| March 31, 2026 | 1,976 | 1,353 | 1,337 | 116 | 143 | 1,415 | 457 | 92 | 406 | 348 |
Trend charts drawn from the standalone income-statement and ratio tables above (oldest year on the left); a gap means that period has no figure. Annual years marked † in the tables are derived from four quarters.
